Erbay Kalay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Erbay Kalay has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Oguz Özbek
Department of Molecular Biology and Genetics, Faculty of Science and Arts, Tokat Gaziosmanpaşa University, Tokat, Türkiye
6 shared publications Osman Nuri Aslan
East Anatolian High Technology Application and Research Center, Ataturk University, Erzurum, Turkey
6 shared publications- Onur Cem Altunoluk
Department of Chemistry, Faculty of Science and Arts, Tokat Gaziosmanpaşa University, Tokat, Türkiye
5 shared publications - Engin Şahin
Department of Nutrition and Dietetics, Faculty of Health Sciences, Bayburt University, Bayburt, Turkey
4 shared publications - Feyzi Sinan Tokalı
Department of Material and Material Processing Technologies, Kars Vocational School Kafkas University Kars Türkiye
4 shared publications - Osman Nuri Aslan
Atatürk Universitesi
4 shared publications
Latest Publications
- Open Access
- 28 March 2026
- Published by Springer Nature in BMC Chemistry
- Vol. 20 (1)
Synthesis of new rhodanine derivative molecules, their biological properties and sensor applications in environmental samples
In this study, two new rhodanine derivative molecules (3 and 4) were synthesized, and the potentiometric sensor properties and certain biological functions
- 28 March 2026
- Published by Springer Nature in BMC Chemistry
- Vol. 20 (1)
Open AccessSynthesis of new rhodanine derivative molecules, their biological properties and sensor applications in environmental samples
In this study, two new rhodanine derivative molecules (3 and 4) were synthesized, and the potentiometric sensor properties and certain biological functions
- 7 February 2026
- Published by Springer Nature in Ionics
- Vol. 32 (3) , 3521-3534
Synthesis of novel 5–arylidene rhodanine derivative molecules for the potentiometric detection of Nd3+ ions
- 7 February 2026
- Published by Springer Nature in Ionics
- Vol. 32 (3) , 3521-3534
Synthesis of novel 5–arylidene rhodanine derivative molecules for the potentiometric detection of Nd3+ ions
- 30 January 2026
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1359
C5-arylidene rhodanine scaffolds from L-phenylalanine and core structures: Synthesis and anticancer evaluation
- 30 January 2026
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1359
C5-arylidene rhodanine scaffolds from L-phenylalanine and core structures: Synthesis and anticancer evaluation
- 6 November 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (3) , 4385-4400
Rhodanine–Sulfonate hybrids targeting aldose reductase: Synthesis, in vitro inhibition, molecular docking, and cytotoxicity studies
Aldose reductase (ALR2), a key enzyme in the polyol pathway, plays a significant role in the onset and progression of diabetic complications, rendering it a critical pharmacological target. In this study, a novel series of twenty-four sulfonate ester-functionalized rhodanine derivatives (compounds 1–24) were rationally designed, synthesized via Knoevenagel condensation, and comprehensively evaluated for their inhibitory activity against ALR2. Spectroscopic and spectrometric methods confirmed the structural integrity of the synthesized compounds. In vitro enzyme inhibition assays revealed that all compounds acted as competitive inhibitors, with several analogues, particularly compounds 6 and 8, exhibiting stronger ALR2 inhibition (Ki = 0.43 µM and 0.48 µM, respectively) than the reference drug epalrestat (Ki = 0.98 µM). Structure–activity relationship (SAR) analysis highlighted the critical influence of para-substituted electron-donating (e.g., methyl) and electron-withdrawing (e.g., nitro, halogen) groups on binding potency. Molecular docking of the most potent inhibitor (compound 6) demonstrated a stable binding pose supported by key interactions, including hydrogen bonding with His110 and π–π stacking with Phe122. In silico ADME profiling confirmed favorable drug-likeness properties for all derivatives. Cytotoxicity studies on L929, A549, and RG-2 cell lines revealed that most compounds were less toxic than the reference drug at lower concentrations, with compound 8 showing a promising cytotoxic profile. These findings position rhodanine–sulfonate hybrids as promising scaffolds for the development of next-generation ALR2 inhibitors for the treatment of diabetic complications.
- 6 November 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (3) , 4385-4400
Rhodanine–Sulfonate hybrids targeting aldose reductase: Synthesis, in vitro inhibition, molecular docking, and cytotoxicity studies
Aldose reductase (ALR2), a key enzyme in the polyol pathway, plays a significant role in the onset and progression of diabetic complications, rendering it a critical pharmacological target. In this study, a novel series of twenty-four sulfonate ester-functionalized rhodanine derivatives (compounds 1–24) were rationally designed, synthesized via Knoevenagel condensation, and comprehensively evaluated for their inhibitory activity against ALR2. Spectroscopic and spectrometric methods confirmed the structural integrity of the synthesized compounds. In vitro enzyme inhibition assays revealed that all compounds acted as competitive inhibitors, with several analogues, particularly compounds 6 and 8, exhibiting stronger ALR2 inhibition (Ki = 0.43 µM and 0.48 µM, respectively) than the reference drug epalrestat (Ki = 0.98 µM). Structure–activity relationship (SAR) analysis highlighted the critical influence of para-substituted electron-donating (e.g., methyl) and electron-withdrawing (e.g., nitro, halogen) groups on binding potency. Molecular docking of the most potent inhibitor (compound 6) demonstrated a stable binding pose supported by key interactions, including hydrogen bonding with His110 and π–π stacking with Phe122. In silico ADME profiling confirmed favorable drug-likeness properties for all derivatives. Cytotoxicity studies on L929, A549, and RG-2 cell lines revealed that most compounds were less toxic than the reference drug at lower concentrations, with compound 8 showing a promising cytotoxic profile. These findings position rhodanine–sulfonate hybrids as promising scaffolds for the development of next-generation ALR2 inhibitors for the treatment of diabetic complications.
- 4 November 2025
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 106 (5) , e70198
Sulfonyl Hydrazone Derivatives Targeting Glutathione Reductase: A Potential Strategy for Redox Modulation in Cancer
Glutathione reductase (GR) plays a pivotal role in cellular metabolism by maintaining redox balance and sulfhydryl homeostasis through the regeneration of reduced glutathione (GSH). In tumor cells, GR is overexpressed, supporting enhanced antioxidant defenses and neutralizing the detrimental effects of reactive oxygen species. In this study, a series of sulfonyl hydrazone analogs bearing phenolic Mannich base moieties were synthesized and characterized as potential GR inhibitors. The compounds exhibited inhibitory activity with IC 50 values ranging from 198.1 to 3013 nM. In silico analyses revealed that 6a binds to the NADP + binding site of the hGR enzyme and interacts with key residues involved in electron transfer, leading to reduced enzyme activity. Compound 6a , the most potent hGR enzyme inhibitor identified in this study, exhibited cytotoxic effects against MCF‐7, A549, and HeLa cancer cell lines with EC 50 values of ~1.52, ~17.5, and ~8.82 mM, respectively. Notably, compound 6a demonstrated only weak cytotoxicity at the millimolar level, particularly against the MCF‐7 cell line. Given its strong inhibitory activity toward the hGR enzyme, enhancing the membrane permeability of compound 6a may improve its cellular uptake and potency, thereby supporting its potential as a promising anticancer drug candidate.
- 4 November 2025
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 106 (5) , e70198
Sulfonyl Hydrazone Derivatives Targeting Glutathione Reductase: A Potential Strategy for Redox Modulation in Cancer
Glutathione reductase (GR) plays a pivotal role in cellular metabolism by maintaining redox balance and sulfhydryl homeostasis through the regeneration of reduced glutathione (GSH). In tumor cells, GR is overexpressed, supporting enhanced antioxidant defenses and neutralizing the detrimental effects of reactive oxygen species. In this study, a series of sulfonyl hydrazone analogs bearing phenolic Mannich base moieties were synthesized and characterized as potential GR inhibitors. The compounds exhibited inhibitory activity with IC 50 values ranging from 198.1 to 3013 nM. In silico analyses revealed that 6a binds to the NADP + binding site of the hGR enzyme and interacts with key residues involved in electron transfer, leading to reduced enzyme activity. Compound 6a , the most potent hGR enzyme inhibitor identified in this study, exhibited cytotoxic effects against MCF‐7, A549, and HeLa cancer cell lines with EC 50 values of ~1.52, ~17.5, and ~8.82 mM, respectively. Notably, compound 6a demonstrated only weak cytotoxicity at the millimolar level, particularly against the MCF‐7 cell line. Given its strong inhibitory activity toward the hGR enzyme, enhancing the membrane permeability of compound 6a may improve its cellular uptake and potency, thereby supporting its potential as a promising anticancer drug candidate.
- Open Access
- 4 May 2025
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 72 (6) , 1752-1762
Novel Sulfonylhydrazones With Sulfonate Ester Framework: Promising Dual Inhibitors of AChE and hCAs
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects millions of individuals worldwide. Treatment strategies for AD vary depending on cognitive and behavioral symptoms, with cholinergic replacement therapy using acetylcholinesterase (AChE) inhibitors being one of the primary approaches. Recent studies have also identified human carbonic anhydrases (hCAs) as significant therapeutic targets for AD, offering new opportunities for the development of innovative treatments. Carbonic anhydrase inhibitors have been shown to prevent early mitochondrial damage and inhibit H 2 O 2 production, thereby reducing amyloid plaque formation. Building on the promising potential of hydrazones particularly sulfonyl hydrazones as anticholinesterase agents, we synthesized 12 novel chlorine‐substituted sulfonyl hydrazone compounds containing aryl sulfonate ester groups. These compounds were evaluated for their inhibitory effects on AChE, hCA I, and hCA II enzymes. The synthesized compounds exhibited low nanomolar inhibitory activity, with K i values ranging from 9.58 ± 2.22 to 104.04 ± 23.82 nM for AChE, 9.12 ± 2.21 to 477.63 ± 218.52 nM for hCA I, and 17.54 ± 7.74 to 564.62 ± 213.98 nM for hCA II. Notably, compound 6 showed strong inhibitory activity against hCA I ( K i = 9.12 ± 2.21 nM; acetazolamide (AZA) = 26.54 ± 3.11 nM) and hCA II ( K i = 17.54 ± 7.74 nM; AZA = 21.73 ± 2.42 nM), whereas compound 4 exhibited superior AChE inhibition ( K i = 9.58 ± 2.22 nM; TAC = 23.12 ± 2.05 nM). The chemical structures of the synthesized compounds were characterized using advanced spectroscopic techniques, including FT‐IR, 1 H‐NMR, and 13 C‐NMR spectroscopy.
- 4 May 2025
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 72 (6) , 1752-1762
Open AccessNovel Sulfonylhydrazones With Sulfonate Ester Framework: Promising Dual Inhibitors of AChE and hCAs
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects millions of individuals worldwide. Treatment strategies for AD vary depending on cognitive and behavioral symptoms, with cholinergic replacement therapy using acetylcholinesterase (AChE) inhibitors being one of the primary approaches. Recent studies have also identified human carbonic anhydrases (hCAs) as significant therapeutic targets for AD, offering new opportunities for the development of innovative treatments. Carbonic anhydrase inhibitors have been shown to prevent early mitochondrial damage and inhibit H 2 O 2 production, thereby reducing amyloid plaque formation. Building on the promising potential of hydrazones particularly sulfonyl hydrazones as anticholinesterase agents, we synthesized 12 novel chlorine‐substituted sulfonyl hydrazone compounds containing aryl sulfonate ester groups. These compounds were evaluated for their inhibitory effects on AChE, hCA I, and hCA II enzymes. The synthesized compounds exhibited low nanomolar inhibitory activity, with K i values ranging from 9.58 ± 2.22 to 104.04 ± 23.82 nM for AChE, 9.12 ± 2.21 to 477.63 ± 218.52 nM for hCA I, and 17.54 ± 7.74 to 564.62 ± 213.98 nM for hCA II. Notably, compound 6 showed strong inhibitory activity against hCA I ( K i = 9.12 ± 2.21 nM; acetazolamide (AZA) = 26.54 ± 3.11 nM) and hCA II ( K i = 17.54 ± 7.74 nM; AZA = 21.73 ± 2.42 nM), whereas compound 4 exhibited superior AChE inhibition ( K i = 9.58 ± 2.22 nM; TAC = 23.12 ± 2.05 nM). The chemical structures of the synthesized compounds were characterized using advanced spectroscopic techniques, including FT‐IR, 1 H‐NMR, and 13 C‐NMR spectroscopy.
- 19 September 2024
- Published by Springer Nature in Chemical Papers
- Vol. 78 (15) , 8321-8332
Synthesis of quinazoline derivatives with new phenolic moieties: in vitro and in silico evaluations as alternative polyphenol oxidase inhibitors
- 19 September 2024
- Published by Springer Nature in Chemical Papers
- Vol. 78 (15) , 8321-8332
Synthesis of quinazoline derivatives with new phenolic moieties: in vitro and in silico evaluations as alternative polyphenol oxidase inhibitors